Head-To-Head Contrast: Omnicell (NASDAQ:OMCL) and Its Peers

Omnicell (NASDAQ: OMCL) is one of 18 public companies in the “Medical Software & Technology Services” industry, but how does it contrast to its rivals? We will compare Omnicell to related companies based on the strength of its institutional ownership, profitability, earnings, valuation, analyst recommendations, dividends and risk.

Institutional and Insider Ownership

59.5% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 3.8% of Omnicell shares are held by insiders. Comparatively, 24.0% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Omnicell and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell 0 1 6 0 2.86
Omnicell Competitors 73 395 772 11 2.58

Omnicell presently has a consensus price target of $51.57, suggesting a potential upside of 0.53%. As a group, “Medical Software & Technology Services” companies have a potential upside of 17.40%. Given Omnicell’s rivals higher probable upside, analysts plainly believe Omnicell has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Omnicell and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Omnicell $680.15 million $42.68 million -233.18
Omnicell Competitors $376.98 million $34.79 million 8.67

Omnicell has higher revenue and earnings than its rivals. Omnicell is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Omnicell has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Omnicell’s rivals have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Omnicell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omnicell -1.14% 0.41% 0.19%
Omnicell Competitors -18.12% -11.70% -2.05%

Summary

Omnicell beats its rivals on 8 of the 13 factors compared.

About Omnicell

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cora Becomes New Manager for Boston Red Sox
Alex Cora Becomes New Manager for Boston Red Sox
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends


Leave a Reply

 
© 2006-2017 BBNS.